Lexaria Bioscience (LEXX) Cash from Operations Growth (3y) (2013 - 2026)
Lexaria Bioscience (LEXX) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Ops. Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
788,338.31 Bn |
788,338.28 Bn |
- |
- |
| 2 |
Belite Bio |
56,560.00 Bn |
56,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,329.30 Bn |
17,329.30 Bn |
- |
- |
| 4 |
Legend Biotech |
3,341.00 Bn |
3,340.71 Bn |
242.10 Mn |
37.40% |
| 5 |
Akari Therapeutics |
1,727.91 Bn |
1,727.91 Bn |
- |
20.11% |
| 6 |
Evaxion A |
1,536.68 Bn |
1,536.67 Bn |
- |
- |
| 7 |
Psyence Biomedical |
238.34 Bn |
238.33 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
113.42 Bn |
106.17 Bn |
2.59 Bn |
16.64% |
| 9 |
Abivax |
95.45 Bn |
95.45 Bn |
- |
- |
| 10 |
Lexaria Bioscience |
7.63 Mn |
2.11 Mn |
20,000.00 |
-20.78% |
| Date | Value |
|---|
| Feb 28, 2026 |
-20.78% |
| Nov 30, 2025 |
7.55% |
| Aug 31, 2025 |
-30.96% |
| May 31, 2025 |
-41.72% |
| Feb 28, 2025 |
-5.45% |
| Nov 30, 2024 |
-32.71% |
| Aug 31, 2024 |
-19.37% |
| May 31, 2024 |
-3.06% |
| Feb 29, 2024 |
12.07% |
| Nov 30, 2023 |
-13.44% |
| Aug 31, 2023 |
-36.38% |
| May 31, 2023 |
-38.62% |
| Feb 28, 2023 |
-17.67% |
| Nov 30, 2022 |
-30.91% |
| Aug 31, 2022 |
-16.90% |
| May 31, 2022 |
-4.56% |
| Feb 28, 2022 |
-28.41% |
| Nov 30, 2021 |
-27.38% |
| Aug 31, 2021 |
-9.94% |
| May 31, 2021 |
-27.37% |
